 Homology Medicines has built a unique gene therapy platform but has experienced a significant stock price decrease due to a COVID-related trial delay and controversy over its gene editing applications. The investment opportunity is to buy the stock on the premise that a resumption of the lead phase 2 trial will act as a positive catalyst for the stock price. 